By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ironwood Pharmaceuticals 

301 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-621-7722 Fax: 617-494-0480


Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our team to passionately pursue excellence. We discovered, developed and are commercializing linaclotide, which is approved in the United States and a number of other countries. Our pipeline priorities include exploring further opportunities for linaclotide, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to address patient needs across the upper and lower gastrointestinal tract. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. Connect with us at or on Twitter at

Key Statistics

Ownership: Public

Web Site: Ironwood
Symbol: IRWD


Company News
Ironwood (IRWD) To Host Fourth Quarter And Full-Year 2015 Investor Update Call 2/5/2016 7:31:06 AM
Ironwood (IRWD) Details Strategy To Build Top-Performing Commercial Biotechnology Company 1/11/2016 10:44:00 AM
Ironwood (IRWD) To Present At J.P. Morgan Healthcare Conference 1/5/2016 10:44:50 AM
Astellas (ALPMY) And Ironwood (IRWD) Report Positive Top-Line Data From Phase III IBS-C Trial Conducted In Japan 12/1/2015 10:55:40 AM
Ironwood (IRWD) Reports Positive Top-Line Data From Phase II Trial Of Linaclotide In Adult Patients With Opioid-Induced Constipation 11/30/2015 10:31:52 AM
Ironwood (IRWD) To Present At Credit Suisse 24th Annual Healthcare Conference 11/5/2015 12:42:35 PM
Ironwood (IRWD) Provides Third Quarter 2015 Investor Update 11/4/2015 10:45:10 AM
Ironwood (IRWD) Initiates Clinical Studies Of Soluble Guanylate Cyclase Stimulators IW-1973 And IW-1701 11/3/2015 11:21:41 AM
Ironwood (IRWD) And Allergan (AGN) Initiate Phase IIb Clinical Trial Of Linaclotide Colonic Release In Adults With Irritable Bowel Syndrome With Constipation 11/2/2015 10:20:31 AM
Allergan (AGN) Acquires Rights To Ironwood (IRWD)'s CONSTELLA (Linaclotide) From Almirall In More Than 40 Countries 10/27/2015 7:32:15 AM